Last reviewed · How we verify
NCT03879278
Multiple Ascending Dose Study in Healthy Subjects
Phase 1 trial testing NPT189 in Amyloidosis in 8 participants. Terminated before completion.
27 June 2019
Quick facts
| Lead sponsor | Proclara Biosciences, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 6 March 2019 |
| Primary completion | 27 June 2019 |
| Estimated completion | 27 June 2019 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- NPT189 — full drug profile →
Conditions studied
- Amyloidosis — all drugs for Amyloidosis →
Sponsor
Proclara Biosciences, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a Phase 1, randomized, double-blind, single center, placebo-controlled, multiple ascending dose (MAD) study in a maximum of 3 cohorts of 8 healthy male and female subjects each. Subjects in Cohorts 1, 2 and 3 will receive ascending multiple IV doses of NPT189 or matching placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03879278
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NPT189
Trials testing the same drug.
- NCT03610035 — A Study of NPT189 in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Amyloidosis
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
Other Proclara Biosciences, Inc. trials
Trials by the same sponsor.
- NCT03610035 — A Study of NPT189 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03879278 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Proclara Biosciences, Inc.
- Last refreshed: 19 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879278.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing